Table S11 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

September 2, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The findings demonstrate the potential for a genomic test to improve malignancy detection in melanocytic tumors.
Somatic point mutations and indels were observed in samples from the borderline cohort, highlighting the need for improved diagnostic tools.
An analysis of the borderline cohort focused on identifying unique genomic alterations that can guide malignancy assessments.
The implications of this research point to the necessity for further exploration in genomic testing for more accurate tumor evaluation.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Analysis reveals somatic mutations in the borderline cohort, suggesting improvements in malignancy testing.

Somatic point mutations and indels for each sample in the borderline cohort.

No takes yet. Share an insight, caveat, or question.

Vergara et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share